We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Epidemiology and Control of Mansonella Perstans Infection in Uganda

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00215280
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : April 20, 2007
Ministry of Health, Uganda
Information provided by:
DBL -Institute for Health Research and Development

September 21, 2005
September 22, 2005
April 20, 2007
November 2005
Not Provided
  • microfilariae periodicity patterns
  • epidemiology of M. perstans at community level
  • clinical spectre among infected
  • reduction in microfilaraemia
Same as current
Complete list of historical versions of study NCT00215280 on ClinicalTrials.gov Archive Site
treatment effect on clinical manifestations
Same as current
Not Provided
Not Provided
Epidemiology and Control of Mansonella Perstans Infection in Uganda
Studies on the Epidemiology and Control of Mansonella Perstans Infection in Uganda
Mansonella perstans (M. perstans) infection is widespread in Uganda. Knowledge about the epidemiology of this infection, and of the morbidity it induces is poor, and no effective treatment is available. The study aims at providing data on diagnostic, epidemiological, morbidity and treatment aspects of M. perstans infections in Uganda.

Overall objective: to investigate diagnostic, epidemiological and treatment aspects of M. perstans in Uganda with relevance to control

Specific objectives:

  1. To establish the pattern of diurnal periodicity of M. perstans microfilaraemia in humans
  2. To establish the patterns of M. perstans microfilaraemia and possible clinical manifestations related to this infection in two communities with medium to high endemicity
  3. To determine the efficacy of ivermectin alone and the combination of ivermectin and albendazole on M. perstans microfilaraemia.
Not Provided
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
  • Mansonelliasis
  • Pruritus
  • Lymphoedema
  • Abdominal Pains
Drug: ivermectin and albendazole
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
February 2006
Not Provided

Inclusion Criteria:

  • Individuals >= 5 years with or without M. perstans infection

Exclusion Criteria:

  • Individuals < 5 years
  • Pregnant women
Sexes Eligible for Study: All
5 Years and older   (Child, Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
DBL -Institute for Health Research and Development
Ministry of Health, Uganda
Principal Investigator: Asanta M Asio, Msc Ministry of Health, Uganda
DBL -Institute for Health Research and Development
April 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP